ABO-101 (Arbor Biotechnologies)

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameABO-101 (Arbor Biotechnologies)
Drug Alias NameABO-101
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas12 > CRISPR-Cas12i2Cell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNP
Mechanisms of ActionHydroxyacid oxidase 1 expression inhibitors
TargetsHydroxyacid oxidase 1
Therapy Area/IndicationsPrimary Hyperoxaluria Type 1Hyperoxaluria, Primary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTunisiaGermany +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArbor Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesArbor Biotechnologies IncChiesi Group
Inactive CompaniesN/A
Active IndicationsPrimary Hyperoxaluria Type 1
Inactive IndicationsHyperoxaluria, Primary

Other Information

ATC CodeN/A
Related LinksN/A